Mestag Therapeutics-preview

Mestag-therapeutics

Mestag Therapeutics

Private

Cambridge, EnglandHealthcare & Life Scienceshttps://www.mestagtherapeutics.com

Last Round

Early Funding

Mar 17, 2026

Total Funding Raised

$40M

Company Overview

Mestag Therapeutics is a biotechnology company focused on developing therapeutics for cancer and inflammatory diseases through a research and development platform that leverages insights into activated fibroblast populations to disrupt their effects on immune cells.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

antibody-based therapeuticsfibroblast-immune interaction therapeuticscancer immunotherapy developmentbispecific antibody for solid tumorsfirst-in-class antibody developmentimmunosuppressive tumor microenvironment targetinginflammatory disease antibody therapytertiary lymphoid structure (TLS) induction therapystromal agonist antibody for inflammatory diseasebiotech pharmaceutical partnership modeltherapeutic target discovery platformdrug discovery services for pharma

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Mestag Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Mestag Therapeutics Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Early Funding	Mar 17, 2026

View all Funding Rounds

Key People

Founding team and executive leadership

Pascal Merchiers

Chief Development Officer (CDO)

Executive Team

Mestag Therapeutics Investors

Notable investors and investment history

Investor	Rounds
Forbion Capital Partners	Early Funding
SV Health Investors	Early Funding
GV	Early Funding
Forbion	Early Funding
Northpond Ventures	Early Funding
Johnson & Johnson Innovation - JJDC	Early Funding
Johnson & Johnson Innovation - JJDC, Inc.	Early Funding

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Mar 17, 2026
$40M raised in early funding.

View all signals

Mestag Therapeutics Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Mestag Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Mestag Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, England

Employee Range43

Year Founded2020

Last FundingMar 17, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.